Intuitive Surgical's prelim Q4 revenue beats estimates on higher da Vinci system placements

Intuitive Surgical

14/01/2026 14:16

Overview

Robotic surgery firm's preliminary Q4 revenue rises 19%, beating analyst expectations

Company saw significant growth in procedure volume and system placements

Preliminary results subject to final audit adjustments

Outlook

Company expects worldwide da Vinci procedures to increase 13% to 15% in 2026

Result Drivers

PROCEDURE GROWTH - Worldwide procedure volume grew by 18% in Q4 2025, driven by 17% growth in da Vinci procedures and 44% growth in Ion procedures

SYSTEM PLACEMENTS - The company placed 532 da Vinci systems in Q4 2025, up from 493 in Q4 2024, with significant placements of the da Vinci 5 model

INCREASED UTILIZATION - Average da Vinci system utilization rose by 4% in Q4 2025, driven by adoption of da Vinci 5 in the U.S. and growth in OUS markets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$2.87 bln
$2.72 bln (25 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Intuitive Surgical Inc is $612.50, about 9% above its January 13 closing price of $561.82

The stock recently traded at 58 times the next 12-month earnings vs. a P/E of 50 three months ago

Press Release: ID:nGNXCVtrt

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)